...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Another IPO that shocks!

Apples and oranges.  A vastly different company.  When Zenith can debut for $49 I'll be if favour of an IPO.  Otherwise we would suffer massive dilution.  We just aren't there yet.  How do I know? The last trade just went through at 39 cents US.  That's where we are.  It would crush their ability to do private placements. We don't even qualify for the Nasdaq.  Not that this discussion even matters to what DM will do.

Share
New Message
Please login to post a reply